Analyst Ratings for AbbVie
AbbVie Questions & Answers
The latest price target for AbbVie (NYSE: ABBV) was reported by UBS on August 1, 2022. The analyst firm set a price target for $146.00 expecting ABBV to rise to within 12 months (a possible 3.21% upside). 26 analyst firms have reported ratings in the last year.
The latest analyst rating for AbbVie (NYSE: ABBV) was provided by UBS, and AbbVie maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on August 1, 2022 so you should expect the next rating to be made available sometime around August 1, 2023.
While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a maintained with a price target of $154.00 to $146.00. The current price AbbVie (ABBV) is trading at is $141.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.